A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Phase 1a is an open-label, multi-dose, single-arm, dose-escalation study to define the
toxicity profile, pharmacokinetics, and antitumor activity of SGN-33 in patients with
myelodysplastic syndrome (MDS), acute myelogenous leukemia(AML), and CD33+ myeloproliferative
diseases. Phase 1b includes patients with AML or MDS treated at the highest tolerated dose
from phase 1a.